| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COX5A |
| Uniprot No | P20674 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 42-150aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSSHGSQET DEEFDARWVT YFNKPDIDAW ELRKGINTLV TYDMVPEPKI IDAALRACRR LNDFASTVRI LEVVKDKAGP HKEIYPYVIQ ELRPTLNELG ISTPEELGLD KV |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COX5A重组蛋白的3篇代表性文献示例(注：文献信息为示例性质，非真实发表论文)：
---
1. **文献名称**: *"Expression and purification of recombinant human COX5A in Escherichia coli for functional studies"*
**作者**: Zhang L, et al.
**摘要**: 该研究成功构建了人源COX5A基因的原核表达载体，并利用大肠杆菌系统高效表达可溶性重组蛋白。通过亲和层析纯化获得高纯度蛋白，验证其与细胞色素c氧化酶复合体的结合能力，为后续酶活性分析提供基础。
2. **文献名称**: *"Structural insights into COX5A's role in mitochondrial respiration through cryo-EM analysis"*
**作者**: Wang Y, et al.
**摘要**: 通过冷冻电镜技术解析了COX5A在哺乳动物线粒体复合体IV中的三维结构，揭示其通过特定结构域稳定氧化酶复合体构象，并调控电子传递效率，为能量代谢疾病机制研究提供结构生物学依据。
3. **文献名称**: *"COX5A overexpression attenuates oxidative stress-induced apoptosis in neuronal cells"*
**作者**: Chen R, et al.
**摘要**: 研究发现重组COX5A蛋白在神经元细胞中过表达可通过增强线粒体膜电位、减少ROS生成，显著抑制氧化应激诱导的细胞凋亡，提示其在神经退行性疾病中的潜在治疗价值。
---
**注**：以上文献为模拟示例，实际研究中建议通过PubMed、Web of Science等数据库检索最新论文。COX5A研究多聚焦于其在线粒体功能调控、癌症代谢重编程及神经保护中的作用。
**Background of COX5A Recombinant Protein**
Cytochrome c oxidase subunit 5A (COX5A) is a nuclear-encoded subunit of cytochrome c oxidase (COX), the terminal enzyme in the mitochondrial electron transport chain (ETC) responsible for catalyzing oxygen reduction and coupling electron transfer to proton pumping, essential for ATP synthesis. As a key component of Complex IV, COX5A contributes to the structural stability and catalytic efficiency of the enzyme.
COX5A exists in two tissue-specific isoforms (COX5A and COX5B) across eukaryotes, with COX5A predominantly expressed in tissues requiring high metabolic activity, such as the heart, liver, and skeletal muscle. Its expression is regulated by metabolic demands, hypoxia, and mitochondrial biogenesis pathways. Dysregulation of COX5A has been linked to mitochondrial disorders, cancer, and neurodegenerative diseases, highlighting its role in cellular energy homeostasis and disease pathogenesis.
Recombinant COX5A protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cell lines) to enable large-scale production for functional studies. The recombinant form retains the conserved domains critical for COX assembly, including a transmembrane helix and conserved residues for heme-copper center coordination. Purification typically involves affinity chromatography followed by refolding steps to ensure proper conformation.
Studies utilizing recombinant COX5A have advanced understanding of COX assembly mechanisms, enzyme kinetics, and interactions with other subunits or regulatory proteins. It also serves as a tool for investigating mitochondrial dysfunction in diseases like Alzheimer’s, where COX activity is impaired, or in cancers with altered metabolic profiles. Additionally, recombinant COX5A supports drug discovery efforts targeting mitochondrial respiration pathways.
Overall, COX5A recombinant protein provides a versatile platform for dissecting the molecular basis of mitochondrial energy metabolism and its implications in health and disease.
×
